Cytokine Storm and Laboratory TestingEducational Resources for you
Background
While most people with COVID-19 exhibit mild symptoms, approximately one in five develop severe pneumonia.1 Of severe COVID-19 patients, approximately 5% develop a systemic dysregulated cytokine response.1,2 This extreme immune response, called cytokine storm (CS), is associated with severe COVID-19 disease and can cause widescale cellular and organ tissue damage.
The use of inflammation, tissue and organ damage biomarkers can help clinicians understand the severity of the disease and implement timely interventions for COVID-19 patients at risk for CS.
High serum levels of pro- and anti-inflammatory cytokines were found in patients with severe COVID-19.3,4 IL-6 levels were higher in COVID-19 patients with severe disease.3,5Ìý
Tissue and organ damage in patients with CS can be monitored with a variety of laboratory tests.6Ìý
Educational Resources
Staying Ahead of Cytokine Storm
Testing for Key Inflammation Markers
AACC webinar: Cytokine Storm Syndrome and COVID-19
Dr. Randy Cron discusses criteria for identifying cytokine storm syndrome (CSS) in patients, complications, and available potential treatments, which include glucocorticoids but also targeted therapies that dampen pro-inflammatory cytokines such as interleukin-1 (IL-1) and IL-6.
Speaker:
Randy Cron, MD, PhD
University of Alabama at Birmingham
Did this information help you?
IMMULITE TNFα, ±õ³¢-1ß, IL2R, IL-6, IL-8, and IL-10, Atellica IM IL- 6, BN and Atellica NEPH SAA assays are not FDA cleared/approved for sale in the U.S.
Some or all uses of the analytes described have not been approved or cleared by the FDA.
